Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gabapentin
Drug ID BADD_D00981
Description Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993.[L8717] It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.[A14097,A186179] Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.[A186143,A185981,L8717]. It is structurally and functionally related to another GABA derivative, [pregabalin].
Indications and Usage For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.
Marketing Status Prescription; Discontinued
ATC Code N03AX12
DrugBank ID DB00996
KEGG ID D00332
MeSH ID D000077206
PubChem ID 3446
TTD Drug ID D0J0ZS
NDC Product Code 60760-066; 70010-118; 42582-116; 71093-162; 60760-517; 70518-2912; 60760-741; 63187-909; 69434-043; 71335-1018; 80425-0128; 69097-812; 51224-119; 55154-6846; 80425-0097; 70166-751; 50436-0428; 50436-0383; 61919-417; 68071-4784; 71610-631; 69097-811; 17856-0600; 64380-868; 76282-706; 43602-470; 76420-014; 59762-4355; 80425-0079; 0228-2637; 71610-146; 69097-814; 67877-224; 53002-3423; 0904-6586; 68071-2458; 68071-3086; 42582-115; 55154-3363; 68788-9509; 60687-580; 61919-350; 63187-785; 17351-5010; 63275-9970; 31722-167; 68071-4978; 50090-5045; 80425-0150; 71205-619; 71093-122; 63629-8488; 0904-6823; 63629-3063; 68071-4113; 52427-803; 71610-421; 16714-662; 52427-806; 71205-931; 65162-102; 55700-780; 70518-1469; 68071-4049; 63187-148; 69097-813; 71335-1348; 68071-3230; 53002-4423; 45865-405; 71610-432; 69434-044; 68788-7839; 70934-123; 57884-2002; 65841-706; 71335-2005; 65015-740; 71093-161; 65862-198; 50436-4290; 55154-7992; 43602-471; 71093-163; 50090-3912; 68788-7941; 69097-943; 62207-924; 68788-7098; 58657-720; 0615-8340; 69844-056; 70010-927; 45963-556; 62207-926; 63739-236; 71335-2004; 71335-0073; 43547-384; 43353-081; 50090-0896; 68788-7135; 0071-0805; 55370-004; 67296-1709; 59088-725; 70010-109; 71335-1997; 0071-0803; 55154-8194; 71335-1200; 43063-664; 70934-339; 71335-1041; 57884-2001; 43063-673; 72189-113; 42582-114; 62756-138; 62207-928; 62756-137; 50090-5125; 50090-4445; 71335-1454; 63187-010; 71335-1198; 68001-412; 50228-177; 71335-1026; 70010-926; 60760-067; 62756-204; 68788-7757; 55700-950; 59762-5050; 0615-8342; 71335-1313; 50090-5322; 55154-7989; 50228-178; 71205-457; 51407-048; 68788-7848; 63739-591; 16714-663; 71335-1490; 50228-181; 67296-1710; 50090-4893; 69367-132; 0395-8055; 76282-627; 42765-018; 62207-923; 53002-6423; 71335-0254; 68788-7104; 57884-0010; 43547-389; 60687-507; 55700-584; 72189-178; 0228-2636; 58657-722; 62756-202; 71335-0351; 60687-591; 55700-544; 55154-3366; 65162-698; 63187-983; 80425-0034; 69367-344; 65862-199; 70120-123; 43353-075; 67877-223; 50268-352; 60760-605; 67877-429; 71335-1093; 71610-442; 71335-0820; 71335-1601; 71610-400; 80425-0149; 63187-988; 72189-109; 71610-125; 61919-660; 70518-0810; 76420-047; 46144-104; 31722-150; 72789-123; 71205-160; 63187-392; 68788-7444; 69844-055; 65862-385; 59762-5025; 80425-0163; 70518-1288; 10135-647; 71610-135; 55154-6845; 68788-7847; 71335-1496; 70518-2776; 67296-1721; 70518-2614; 65862-523; 53746-102; 43547-385; 80425-0036; 63187-149; 42806-511; 42192-608; 65862-524; 68788-7869; 71610-059; 71610-426; 62207-927; 71205-532; 60592-300; 80425-0031; 51224-219; 68071-1292; 55700-815; 71610-410; 68788-7614; 65977-0054; 71335-1287; 71205-317; 71610-090; 63629-8060; 71205-929; 65841-705; 70010-928; 71093-112; 60687-602; 59762-4135; 68554-0128; 59762-4460; 68071-2600; 45865-356; 71335-1497; 70518-3330; 70518-2098; 70934-933; 71335-0993; 70518-0483; 63739-903; 80425-0035; 68382-205; 61919-640; 64380-867; 63739-904; 50228-180; 72189-092; 69367-135; 69097-815; 69367-347; 71610-195; 70518-1160; 72789-055; 59762-4030; 76282-707; 70518-2493; 71610-185; 16714-503; 80425-0033; 63187-248; 16714-661; 72789-127; 71205-932; 63629-7309; 60760-088; 63629-8492; 62756-139; 63629-8489; 31722-149; 63187-031; 43602-469; 52048-1980; 0071-0513; 76282-323; 68788-7431; 45963-555; 49483-607; 70934-593; 25000-105; 68382-204; 35356-708; 55700-949; 70934-651; 53002-5472; 68071-2308; 59762-4240; 71335-1453
Synonyms Gabapentin | 1-(Aminomethyl)cyclohexaneacetic Acid | Neurontin | Gabapentin Hexal | Convalis | Gabapentin-Ratiopharm | Gabapentin Ratiopharm | Novo-Gabapentin | Novo Gabapentin | NovoGabapentin | PMS-Gabapentin | Apo-Gabapentin | Apo Gabapentin | ApoGabapentin | Gabapentin Stada
Chemical Information
Molecular Formula C9H17NO2
CAS Registry Number 60142-96-3
SMILES C1CCC(CC1)(CC(=O)O)CN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AkathisiaD(1A) dopamine receptorP21728T2211811715630; 15738862; 15959450; 15627046
AnxietyMuscarinic acetylcholine receptor M1P11229T2889311715630; 15738862; 15959450; 15627046
Anxiety5-hydroxytryptamine receptor 3AP46098T6459111715630; 15738862; 15959450; 15627046
AnxietyAlpha-1A adrenergic receptorP35348T9260911715630; 15738862; 15959450; 15627046
Anxiety5-hydroxytryptamine receptor 2BP41595T3120411715630; 15738862; 15959450; 15627046
Anxiety5-hydroxytryptamine receptor 2AP28223T3206011715630; 15738862; 15959450; 15627046
AnxietyHistamine H1 receptorP35367T7791311715630; 15738862; 15959450; 15627046
Diabetic complications NECTransforming growth factor beta-1 proproteinP01137T9725711163803; 12802498; 10997922
Diabetic complications NECGlutamine--fructose-6-phosphate aminotransferase [isomerizing] 1Q06210Not Available11163803; 12802498; 10997922
Diabetic complications renalTransforming growth factor beta-1 proproteinP01137T9725711163803; 12802498; 10997922
Diabetic complications renalGlutamine--fructose-6-phosphate aminotransferase [isomerizing] 1Q06210Not Available11163803; 12802498; 10997922
DystoniaD(1A) dopamine receptorP21728T2211811715630; 15738862; 15959450; 15627046
Nausea5-hydroxytryptamine receptor 2AP28223T3206011715630; 15738862; 15959450; 15627046
NauseaHistamine H1 receptorP35367T7791311715630; 15738862; 15959450; 15627046
Nausea5-hydroxytryptamine receptor 3AP46098T6459111715630; 15738862; 15959450; 15627046
NauseaMuscarinic acetylcholine receptor M1P11229T2889311715630; 15738862; 15959450; 15627046
NauseaAlpha-1A adrenergic receptorP35348T9260911715630; 15738862; 15959450; 15627046
Nausea5-hydroxytryptamine receptor 2BP41595T3120411715630; 15738862; 15959450; 15627046
PainNot AvailableQ5SUY9Not Available9168217; 9655623
ParkinsonismD(1A) dopamine receptorP21728T2211811715630; 15738862; 15959450; 15627046
Sleep disturbances (incl subtypes)5-hydroxytryptamine receptor 2AP28223T3206011715630; 15738862; 15959450; 15627046
Sleep disturbances (incl subtypes)Histamine H1 receptorP35367T7791311715630; 15738862; 15959450; 15627046
Sleep disturbances (incl subtypes)5-hydroxytryptamine receptor 3AP46098T6459111715630; 15738862; 15959450; 15627046
Sleep disturbances (incl subtypes)Muscarinic acetylcholine receptor M1P11229T2889311715630; 15738862; 15959450; 15627046
Sleep disturbances (incl subtypes)Alpha-1A adrenergic receptorP35348T9260911715630; 15738862; 15959450; 15627046
Sleep disturbances (incl subtypes)5-hydroxytryptamine receptor 2BP41595T3120411715630; 15738862; 15959450; 15627046
Tardive dyskinesiaD(1A) dopamine receptorP21728T2211811715630; 15738862; 15959450; 15627046
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood potassium increased13.11.01.0110.000153%Not Available
Blood pressure abnormal13.14.03.001--Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood sodium decreased13.11.01.012--Not Available
Blood urea abnormal13.13.01.005--Not Available
Blood urine13.13.02.0110.000051%Not Available
Body mass index decreased13.15.01.0250.000102%Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.002--Not Available
Bradykinesia17.01.02.004--Not Available
Bradypnoea22.02.01.0020.000356%Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Breast enlargement21.05.04.001--Not Available
Breast feeding26.05.01.001--Not Available
Breast pain21.05.05.003--
Bronchiolitis22.03.02.004; 11.05.04.0080.000127%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.012--
Burning sensation17.02.06.001; 08.01.09.0290.000915%Not Available
Bursitis15.04.01.0010.000102%Not Available
C-reactive protein increased13.09.01.007--Not Available
Capillary fragility increased13.01.02.022--Not Available
Cardiac arrest02.03.04.0010.000411%
Cardiac failure02.05.01.001--
Cardiac failure acute02.05.01.0050.000153%Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardiac murmur13.14.01.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 36 Pages